Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006434
Abstract: Key Points Long-term RESONATE-2 data show sustained PFS and OS benefits (medians not reached) for first-line ibrutinib treatment in patients with CLL. Forty-two percent of patients continued ibrutinib for up to 8 years; dose management… read more here.
Keywords: ibrutinib; treatment patients; first line; line ibrutinib ... See more keywords